mivebresib + navitoclax

This is a **combination therapy** consisting of two small molecule inhibitors: **mivebresib**, a potent inhibitor of bromodomain and extra-terminal motif (BET) proteins, and **navitoclax**, an inhibitor of the BCL-2 family of anti-apoptotic proteins. **Mivebresib** functions as an epigenetic modulator by inhibiting BET proteins, leading to downregulation of genes such as MCL1 and induction of apoptosis in cancer cells, particularly in hematological malignancies. **Navitoclax** targets and inhibits multiple BCL-2 family proteins (BCL-2, BCL-xL, BCL-w), promoting apoptosis by disrupting cancer cell survival mechanisms. Preclinical and early clinical studies suggest synergy between BET inhibition (mivebresib) and BCL-2 inhibition (navitoclax) in acute myeloid leukemia (AML) and myelofibrosis, providing a rationale for the combination in these indications. The combination is under clinical investigation, primarily for hematologic cancers[1][5].